title: [Comparison of EGFR mutation status in paired pre- and post-chemotherapy serum for advanced pulmonary adenocarcinoma].
abstract: OBJECTIVE
  Non-small cell lung cancer (NSCLC) with mutations in the epidermal growth factor receptor (EGFR) is a distinct subgroup of NSCLC, which is particularly responsive to EGFR tyrosine kinase inhibitors (TKIs). The aim of this study is to detect EGFR mutations in paired serum of pre- and post-chemotherapy from advanced pulmonary adenocarcinoma patients to evaluate impact of chemotherapy on EGFR mutation status.
  
  
  METHODS
  Magnetic beads were used for DNA extraction from paired serum of pre- and post-chemotherapy of 33 advanced pulmonary adenocarcinoma patients. The EGFR exon 19 and 21 were amplified by mutant-enriched nested PCR and analyzed by direct sequencing.
  
  
  RESULTS
  EGFR mutations were detected in 39.4% (13/33) and 54.5% (18/33) serum samples of pre- and postchemotherapy, respectively. The EGFR mutation status was consistent in 54.5% (18/33) patients. Among 15 discordant cases, 10 changed from pre-chemo wild-type to post-chemo mutant-type status, while 5 from pre-chemo mutant-type to post-chemo wild-type status.
  
  
  CONCLUSIONS
  Chemotherapy may have influence on serum EGFR mutation status in advanced adenocarcinoma patients.
authors.affiliation: Department of Respiratory Disease, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
authors.forename: Rubing
authors.initials: R
authors.lastname: Han
authors.forename: Wei
authors.initials: W
authors.lastname: Zhong
authors.forename: Jing
authors.initials: J
authors.lastname: Zhao
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Ying
authors.initials: Y
authors.lastname: Xia
authors.forename: Han
authors.initials: H
authors.lastname: Wang
authors.forename: Longyun
authors.initials: L
authors.lastname: Li
authors.forename: Mengzhao
authors.initials: M
authors.lastname: Wang
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000235:genetics*; D000328:Adult; D000368:Aged; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000097:blood* / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000528:radiation effects; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors